Nov 25, 2024
Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal(TM)
Jan 08, 2024
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
Feb 03, 2021
Guardant360 CDx submitted for regulatory approval in Japan
Nov 22, 2019
Guardant Health AMEA wins this year's Growth Excellence Leadership Award by Frost & Sullivan
Oct 19, 2018
Guardant Health Presents Data on Immunotherapy-related Biomarkers MSI and TMB in blood of advanced cancer patients at European Society of Medical Oncology Annual Meeting
Oct 16, 2018
Lung Cancer Study Published in JAMA Oncology Shows Guardant360 Outperforms Tissue Biopsy Alone in Identification of Targetable Mutations
Jul 19, 2018
New Nature Medicine Study Demonstrates Ability of The Guardant360 Assay to Predict Patient Response to Immunotherapy in Advanced Gastric Cancer Patients
Jul 12, 2018
Guardant Health Appoints Leena Das-Young to Lead Efforts to Develop Liquid Biopsy Products for Early-Stage Cancer Applications
Jul 12, 2018
Guardant Health Announces Medicare Coverage for the Guardant360 Assay in Non-Small Cell Lung Cancer
May 23, 2018
Guardant Health to Present 29 Abstracts at ASCO Advancing the Science of Liquid Biopsy Across Multiple Indications and Applications
Apr 26, 2018
Guardant Health Publishes Extensive Validation of Guardant360® Assay Comprising Largest-Published Blood-Tissue Comparison
Apr 13, 2018
Guardant Health to Present Validation Data for the GuardantOMNI(TM) assay
Mar 12, 2018
Guardant Health and National Cancer Center East Japan Announce Liquid Biopsy Arm of Lung Cancer Trial
Mar 12, 2018
Guardant Health and National Cancer Center East Japan Announce Liquid Biopsy Arm of GI Cancer Trial
Feb 15, 2018
The Guardant360® Assay Receives Expedited Access Pathway Designation for Breakthrough Devices from FDA
Nov 16, 2017
Guardant Health Expands Support for the Development of the GuardantOMNI(TM) Assay Through New Agreement with Bristol-Myers Squibb
Nov 15, 2017
New Research Reveals Molecular Heterogeneity of Metastatic Gastroesophageal Cancer
Nov 06, 2017
Guardant Health Database Reveals Potential of Targeted Therapy Combinations to Treat Advanced Lung Cancer
Oct 02, 2017
Study Demonstrates Potential for the Guardant360 Assay® to Predict Which Patients Will Benefit from Immunotherapy
Sep 26, 2017
Guardant Health Receives Investigational Device Exemption Approval from the FDA to Support Merck KGaA, Darmstadt, Germany Tepotinib Study